A Phase I Study of RGT-419B in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer or Other Solid Tumors
PHASE1Active, not recruitingINTERVENTIONAL
Enrollment
40
Participants
Timeline
Start Date
April 17, 2023
Primary Completion Date
July 30, 2025
Study Completion Date
July 30, 2025
Conditions
Breast CancerAdvanced Solid Tumor
Interventions
DRUG
RGT-419B
RGT-419B will be administered orally
Trial Locations (1)
200032
Fudan University Shanghai Cancer Center, Shanghai
All Listed Sponsors
lead
Regor Pharmaceuticals Inc.
INDUSTRY
NCT06299124 - A Phase I Study of RGT-419B in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer or Other Solid Tumors | Biotech Hunter | Biotech Hunter